<DOC>
	<DOCNO>NCT00298883</DOCNO>
	<brief_summary>Trial use Myfortic reduce anti-HLA alloantibody patient wait renal transplantation .</brief_summary>
	<brief_title>Desensitization Renal Transplant Candidates</brief_title>
	<detailed_description>Pre-formed HLA antibody prevent renal transplantation risk hyperacute rejection . We propose prospective study evaluate efficacy Enteric Coated Mycophenolate Sodium ( Myfortic ) decrease titer anti-HLA alloantibody patient await kidney transplantation . Myfortic immunosuppressant inhibits proliferation B T cell block enzyme inosine monophosphate dehydrogenase . We attempt determine whether 6-week course Myfortic adequately decrease antibody reactivity level compatible transplantation .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patients decease donor kidney transplant wait list panel reactive antibody &gt; 50 % live donor wait list patient history positive crossmatch ( donorspecific antibody ) eligible study . Any subject meeting Inclusion Criteria Subjects unable attend weekly clinic visit six week Inability tolerate Myfortic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Renal</keyword>
	<keyword>Transplant</keyword>
	<keyword>PRA</keyword>
</DOC>